New Weight-Loss shot enters first human safety trial
NCT ID NCT07518589
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an experimental drug called CMS-D008 in 110 healthy and overweight or obese adults. The main goal is to check safety and how the body processes the drug, not weight loss. Participants will receive either the drug or a placebo as injections, and researchers will monitor vital signs, lab tests, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CMS-D008 (an experimental biologic injection)
- What this could lead to
- If successful, this could point toward a new treatment for weight management in overweight or obese adults.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not weight loss. It is small (110 people) and may not show meaningful benefits or lead to a marketed drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily participate in this study, sign the informed consent form, be able to understand and comply with all requirements and restrictions of the study, and complete the study in accordance with the protocol. 2. Male or female aged 18-56 years (inclusive) 3. Body mass index (BMI) ≥23 kg/m2 at screening, with stable body weight in the past 4 months 4. Glycated hemoglobin (HbA1c) \< 6.5% and fasting plasma glucose \< 7 mmol/L at screening. 5. Participants of childbearing potential (including their partners) have no plan to conceive, donate oocytes, or donate sperm from the date of signing the informed consent form until 7 months after the last study drug administration, and must comply with contraceptive requirements during this period Exclusion Criteria: 1. History or presence of liver disease (except fatty liver disease), allergy, cardiovascular, endocrine (except primary obesity), neuropsychiatric, digestive, respiratory, hematological, immune, or genitourinary system major diseases. 2. History or presence of endocrine diseases that may significantly affect body weight, or obesity caused by medication use, single gene mutation, or genetic obesity syndromes. 3. Any skin conditions that may interfere with the assessment of injection-site reactions. 4. Use of any siRNA agent in the prior 12 months 5. Use of glucagon-like peptide-1 (GLP-1) receptor agonists and other weight-loss medications in the past 6 months. 6. Use of any prescription or non-prescription drugs (including Chinese herbal medicines, vitamins, minerals, and dietary supplements, etc.) within 2 weeks before dosing or at least 5 elimination half-lives, whichever is longer. 7. Participants with clinically significant abnormalities in vital signs, physical examination, laboratory tests, 12-lead ECG, and other auxiliary examinations at screening or baseline, who are considered by the investigator to be ineligible for enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Evaluate the safety and tolerability are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an experimental injection help people with obesity shed pounds?
- A cup of beans a day: could it calm inflammation and boost insulin response?
- Can a new pill help fight obesity? a trial puts HRS-7535 to the test
- Could shedding pounds be the key to silencing chronic back pain?
- Could a new injection help tackle obesity? a safety trial begins
- Can a new injection help tackle obesity and diabetes? a safety trial begins